GSK(US:GSK) Guo Ji Jin Rong Bao·2025-11-07 04:18Core Viewpoint - GSK successfully hosted discussions at the China International Import Expo (CIIE) focusing on systemic lupus erythematosus (SLE), aiming to enhance public awareness and improve patient support and chronic disease management [1][2][3] Group 1: Disease Overview - Systemic lupus erythematosus is a chronic autoimmune connective tissue disease that can damage multiple organs, significantly increasing patient mortality risk [3] - There are over 1 million lupus patients in China, predominantly among women of childbearing age, with improved survival rates due to advancements in diagnosis and treatment [3] Group 2: GSK's Commitment - GSK has been a dedicated partner of the CIIE, leveraging its influence to accelerate the accessibility of innovative drugs and extend support to patients in need [3] - GSK has been focused on the lupus field for over a decade, with its drug Benlysta (belimumab) expanding its indications to meet the needs of Chinese patients [3] Group 3: Patient Management and Treatment - Experts emphasize the importance of early diagnosis and treatment for children with lupus, highlighting the value of biologics like Benlysta in managing the disease effectively [5] - Continuous monitoring and standardized treatment are crucial for patients diagnosed with lupus nephritis to prevent complications and protect kidney function [6][7] Group 4: Collaborative Efforts - GSK is actively collaborating with various organizations to establish a standardized national lupus treatment system, aiming to improve patient outcomes [7] - Since signing a strategic cooperation memorandum with GSK, significant progress has been made in disease education and patient care, with expectations for further collaboration to enhance the quality of life for lupus patients in China [7]